Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 102, Issue 4, Pages 688-700Publisher
WILEY
DOI: 10.1002/cpt.690
Keywords
-
Categories
Funding
- European Union [668353]
- Swedish Research Council [2015-02760, 2016-01153, 2016-01154]
- Swedish Research Council [2015-02760] Funding Source: Swedish Research Council
Ask authors/readers for more resources
Genetic polymorphisms in cytochrome P450 (CYP) genes can result in altered metabolic activity toward a plethora of clinically important medications. Thus, single nucleotide variants and copy number variations in CYP genes are major determinants of drug pharmacokinetics and toxicity and constitute pharmacogenetic biomarkers for drug dosing, efficacy, and safety. Strikingly, the distribution of CYP alleles differs considerably between populations with important implications for personalized drug therapy and healthcare programs. To provide a global distribution map of CYP alleles with clinical importance, we integrated whole-genome and exome sequencing data from 56,945 unrelated individuals of five major human populations. By combining this dataset with population-specific linkage information, we derive the frequencies of 176 CYP haplotypes, providing an extensive resource for major genetic determinants of drug metabolism. Furthermore, we aggregated this dataset into spectra of predicted functional variability in the respective populations and discuss the implications for population-adjusted pharmacological treatment strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available